 2  6 
often also eHealth records. UK Biobank and Generation Scotland were intended to be 1 0 1 resources with minimal restrictions to reuse [8] . Data and sample repositories such as GS 1 0 2 were a manifestation of a growing commitment coming from science policy actors, including 1 0 3 funders, to promote data sharing and access to a wide range of users. In what follows, we 1 0 4 consider the specific characteristics of the GS repository in shaping its data access practices 1 0 5 in light of the UK data sharing policy environment. We will use our interaction with GS to 1 0 6 explore in particular the issues of sustainability and evolution of the content in relation to 1 0 7 ethical decision making around access. We engage with GS as a specific example of a biobank and our "encounters with experience" 1 1 0
[4] gained within the Generation Scotland Access Committee (GSAC). Empirical studies of 1 1 1 the perspectives of those running biobanks point to the need to consider the contextual 1 1 2 aspects of biobanking [11] , [12] , [13] . We hope to further elucidate these contextual aspects by with the imperative to share data as openly as possible. Through GS we explore the entwined 1 1 7 practical and ethical challenges around data sharing for existing repositories [14] . By that our discussion goes beyond considerations of the "what if" type, which for example 1 2 0 balance future health benefits against potential privacy risk questions for an imagined future We reflect upon the processes within GS through which requests for data access are handled. This will include considering how the Access Committee must deal creatively and 1 2 4 responsively with issues not foreseen when the repository was first set up and as a 1 2 5 1 3 2 objects are seamlessly woven into every day practice -family pedigrees are produced, blood 1 3 3 samples are taken, medical records are filed away etc. In some cases the movement of these 1 3 4 material objects into different physical locations, or even the particularity of their 1 3 5 arrangement or configuration, can serve to problematize those practices' [17] . We argue that 1 3 6 data sharing raises issues relating to the role of the repository in future governance and 1 3 7 ethical oversight and how expectations and preferences of participants will be interpreted in 1 3 8 future scenarios, for example within consortia [18] . Whilst issues of sustainability could be 1 3 9 viewed as separate from ethical and governance considerations, we aim to show that they are 1 4 0 inseparable in relation to access [19] . The GS Scottish Family Health Study was designed to provide a research resource, 1 4 4 adequately powered to detect moderate sized genetic effects upon common and chronic 1 4 5 disease and traits. A family-based recruitment strategy was employed to collect over 24,000 population registered with a GP) [20] . Those who indicated that they and one or more of their Whilst the emphasis coming from the wider science and data sharing policy environment 3 0 1 encourages the prioritisation of data sharing [47] , translating this into practice remains a local 3 0 2 enterprise. Requirements for managing access to resources held in biobanks and heterogeneity is detrimental. However, scholarship in the field of science and technology 3 0 6 studies suggests that despite efforts at standardization, practice will necessarily maintain 3 0 7 some aspects of a given context [48] . Unlike for example UK Biobank, GS has made a 3 0 8 commitment to oversee and manage overlap in the research goals of applicants. Where it is 3 0 9 likely that two separate applications would overlap, a situation that has arisen no more than 3 1 0 10 times in the history of GS, leading to a potential duplication of effort, GS offers to put the However, there is no requirement for the applicant to collaborate with an EWG. Academics Some of these academics were involved in the scientific design of the study, the recruitment 3 1 7 of participants and convincing funders of its merit. Moreover, they continue to be involved in what has been termed 'articulation work' [49] . That is to say they (and others) have sought research funding for a variety of studies via which they have added further data to the 3 2 0 resource, helping to maintain its relevance and scientific importance. The EWGs include high profile academics whose expertise covers a particular area of research. Whilst a decision on the part of an applicant not to collaborate with the EWGs does 3 2 3 not necessarily create a barrier to access, the EWGs constitute part of a commitment by 3 2 4 GSAC to manage project overlap. A distinctive feature of access arrangements for GS relates 3 2 5 to co-authorship, which is stated in the data and materials transfer agreement and the GS 3 2 6
Authorship & Acknowledgement Policy [9] . GS requires that collaboration with a research 3 2 7 group requesting access leads to shared authorship of research publications resulting from use 3 2 8 of the GS resource. Whilst there are few sanctions that GS can apply to ensure compliance 3 2 9 with this requirement for attribution of credit, there is just one example of these terms not 3 3 0 being honoured from over 150 completed research projects with more than 100 published 3 3 1 research papers. Some of the experts in governance suggest that the independence of access ways of acknowledging and rewarding those who collect and manage the data [36] . Requests for access to data only or data plus samples are submitted via a secure online portal, where researchers will also indicate whether linkage to NHS records or participant re-contact 3 3 9 will be necessary. Four areas of evaluation (scientific, governance, data and materials) are participants. Issues such as whether the participants will need to be re-contacted and on what 3 4 5 basis are dealt with here. On one occasion, a proposal was declined as it asked for specific 3 4 6 phenotypic information which was thought likely to raise sensitivities such as participants 3 4 7 feeling that they had been "singled out". The data assessment is usually done by a member of 3 4 8 the GS management group who also sits on the GSAC. This will consider the data holdings if an applicant has requested the samples to be sent overseas or has asked to re-contact 3 5 3 participants, the data assessment will include a report on the number of individuals who have to only a small number of individuals and was returned with a request for an overhaul of the 3 5 6 research design, on the grounds that it could pose a potential re-identification risk. The form also includes sections on why the GS resource was chosen to carry out the research and what benefits could be expected to accrue to GS as a result of providing access. Applicants and maintaining the biobank in regard to each proposal is also a question that is raised by asking applicants for further information or modification of the type and scope of access GS access arrangements and the discussion conducted as part of the GSAC meetings aim to 3 7 5 strike a balance that promotes the sustainability of the resource whilst making it a repositories should be well-resourced, presumably to support the sort of activities that 3 7 8 comprise the managed access approach undertaken by GS. Following the end of the period of funding from the Scottish Government, the GS project manager and administrator posts have unwillingness by prospective secondary users to pay an access charge. Sustainability questions also arise in relation to the wider data sharing environment and the 3 9 4 existence of cost free alternatives to accessing genotype and phenotype data [19] broadly 3 9 5 similar to that in GS. For example, access can be sought to resources via routine academic 3 9 6 collaboration with the Principal Investigator of different cohorts, or from genomics data resources such as the EGA [33] . Another evolving aspect of the data environment impacting 3 9 8 upon the GS biobank is requests for data to be released so that it can be housed on platforms within the consortium. For example, data analysts working in a consortium will usually not 4 1 8 have been involved in the data access application made to each repository. This disconnect is Attempts to mitigate these sorts of concerns can be seen in to the central genomics database Committees (DACs) of this resource [50] . Independence in this scenario is interpreted as 4 2 6
'without the involvement of data producers' [50] . Other examples of this sort of centralised 4 2 7 structure for managing access can also be found in the UK. For example, the Wellcome Trust 4 2 8
Sanger Institute DAC manages access to data assembled for the Wellcome Trust Case Control Consortium and other projects located there [52] . While there is an increasingly 4 3 0 acknowledged need to attribute credit for the role played by repositories such as GS, these subjects within these large multi-repository, multi-institutional arrangements, are not directly One of the problems of attempting to produce enduring standardised access procedures is that The number of events, and measurements recorded, increase over time as the participants get GS became a prospective cohort as a result of the ability to link to routine NHS data [53] . were tested for association with over 24 million genetic markers in a genome-wide Alongside anonymisation of data, informed consent is a standard tool for ensuring data access future. For that reason, and due to the logistics and potential confidentiality challenges of 4 7 5
GS and Evolving Participant Consent
contacting and re-consenting individual participants for each use, broad consent was sought 4 7 6 from participants. This was intended to permit a very wide range of potential biomedical relating to access to the resource and the management and protection of participant data. It is 4 8 0 made clear that "Any access will be subject to the strictest ethical scrutiny and scientific to be sent abroad was later obtained for a little under half the cohort (Table 1) . This additional consent was achieved via a re-contact exercise carried out in 2012-3 in 4 9 1 response to several requests to allow the materials and data to be analysed using technologies only available in other countries. Re-contact for consent, as with all re-contact with study 4 9 3 participants, was done through an established mechanism that, again, used the CHI number, to and from 21,207 individuals (88% of the 24,084 people in the study database, excluding 5 0 0 participants who had died or who had not given consent for re-contact). Just over half this taking an increasingly permissive view about the relationship between consent and access to 5 0 7 medical records [38] , GS continues to employ a consent based approach for use of these data. The joint report from the UK National Data Guardian was clear on the responsibility of 5 0 9 organisations using NHS data to ensure not only appropriate consent but also anonymity of 5 1 0 disseminated data [37] . Due to the detailed and potentially identifiable nature of the data 5 1 1 collected in GS, it was agreed from the outset that the data would be released using a accessed without the appropriate authorisation via the access processes detailed above.
2 5
Knowledge of these systems for protecting the data, the data subjects and reputation of the One of the issues highlighted in the paper is the interaction between specific local 5 3 0 characteristics of a given biobank or repository, especially in relation to governance and 5 3 1 sustainability, and the guidelines and ideals pervading the wider data sharing and science 5 3 2 policy and ethics environment, which aim at harmonisation and fewer barriers to access [19] .
3 3
The aim is to show how this policy context translates into the ways in which data is accessed 5 3 4
and ethics and governance are enacted, given factors local to the repository and its practices. One part of this is the ability to respond to what is non-routine, as well as what was not 5 3 6
foreseen when consent arrangements were entered into originally [17] . The GSAC in its 5 3 7 decision-making must consider and accommodate a number of issues, in which it is difficult
to make a clean separation between questions of sustainability, governance and ethics. GSAC routinely discusses issues relating to the welfare of the data subjects, how further 5 4 0 recontacts may be unduly onerous and whether or not a particular request for new data may the Executive Committee and the GSAC is an important part of ensuring that the governance 5 4 6 model agreed to by participants is maintained.
4 7
In considering requests for access, GSAC must "ensure the Project, through its research and management of the GS resource. We suggest that in addition to the focus upon 5 5 9 ever more universal and standardised practices, the local expertise gained in the management 5 6 0 of such repositories must also be nurtured and encouraged [48] . In summary, a commitment to open access in genomics research has found substantial 5 6 3 backing in science and health policy circles in the UK and beyond, as evidenced by the stance Bermuda, Fort Lauderdale and Toronto. This is not to stay that stakeholders are unaware of 5 6 6 or unsympathetic to the issues around data subject privacy and to a lesser extent the interests Statement). However, in this paper we have attempted to throw light on how decisions on 5 6 9 access sustainability can figure in solutions to potential problems for both data-producing 5 7 0 scientists and research participants. Repositories of data and samples from human subjects 5 7 1 may have to operate under managed access, to protect privacy, align with the participant 5 7 2 consent and ensure that the resource can be managed in a responsive and sustainable way. Research on best-practice which looked at literature produced by stakeholders also found that 5 7 4 some of the questions we have raised here, such as continuing to balance the interests of 5 7 5 different stakeholders, fulfilling commitments to research participants and the ability to control analyses that may cause reputational damage, were ranked among the disadvantages 5 7 7 of data sharing [29] . We have used our own engagement with GS in order to construct an placed upon open access to data as a commercial and economic good, some mechanism for 5 8 7
incorporating the role now carried out by the access committee will remain necessary. The processes of participant recruitment to GS:SFHS received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). The data supporting this article are in the public domain. Both authors contributed to the writing of the manuscript, in an iterative manner. The text 6 1 1 was drafted by CH and SK, who have each read and approved the final manuscript. We thank David Porteous, Reka Nagy, Shawn Harmon and Gill Haddow for constructive 6 1 4 comments on drafts of the manuscript. We are indebted to the GS Project Manager and GS 6 1 5
Administrator, Archie Campbell and Laura Boekel, for their helpful responses to our requests 6 1 6 for information on details of access requests and issues arising from these. 
